Ligands of Immunopharmacology

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC 50 values of 0.005 μM and 0.023 μM, respectively.

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitisIn VitroAZD8848 shows good activity against TLR7, with cellular pEC 50 s of 7.0 and 6.6 for human TLR7 and rat

BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC 50 of  59.1 nM for human TLR7 . BBIQ is a powerful vaccine adjuvant that enhances innate immune responsesIn VitroBBIQ induces IFN-α in